Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1994 Nov;39(6):347–359. doi: 10.1007/BF01534421

Patho- and immunobiology of malignant mesothelioma: characterisation of tumour infiltrating leucocytes and cytokine production in a murine model

H Bielefeldt-Ohmann 1,✉, D R Fitzpatrick 1, A L Marzo 1, A G Jarnicki 1, R P Himbeck 1, M R Davis 1, L S Manning 1, B W S Robinson 1
PMCID: PMC11041107  PMID: 8001022

Abstract

Malignant mesothelioma (MM) is an aggressive, uniformly fatal serosal tumour, usually associated with asbestos exposure, for which there currently is no effective treatment. In order to gain insight into the mechanism(s) whereby MM might escape immune surveillance, a murine model for MM was used (a) to characterise the tumour-infiltrating lymphocytes (TIL) and macrophages (TIM) phenotypically, (b) to examine systemic immune recognition of MM, and (c) to examine the possible influence of tumour-derived cytokines on systemic and local pathobiological manifestations of MM. A profound down-regulation of lymphocyte surface markers, known to be infolved in T cell activation, was found in TIL. Likewise, although TIM were present in large numbers, their expression of MHC class II antigen and integrins was weak or absent, suggestive of altered functional activity. Significant amounts of cytokines, in particular transforming growth factor β, interleukin-6 (IL-6), IL-1 and tumour necrosis factor were produced during the course of MM tumour development-directly by the MM cells and/or indirectly in response to tumour growth. These factors may contribute both to derangement of antitumour effector mechanisms and to the clinical and pathological manifestations of the disease.

Key words: Malignant mesothelioma, TIL, CD3, TGFß, Interleukin-6

References

  • 1.Abraham E, Chang Y-H. Haemorrhage-induced alterations in function and cytokine production of T cells and T cell subpopulations. Clin Exp Immunol. 1992;90:497. doi: 10.1111/j.1365-2249.1992.tb05873.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Alarcon B, Ley SC, Sanchez-Madrid F, Blumberg RS, Ju ST, Fresno M, Terhorst C. The CD3-ψ and CD3-δ subunits of the T cell antigen receptor can be expressed within distinct functional TCR/CD3 complexes. EMBO J. 1991;10:903. doi: 10.1002/j.1460-2075.1991.tb08023.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Bielefeldt-Ohmann H. Double immuno-labeling systems for phenotyping of immune cells harboring bovine viral diarrhoea virus. J Histochem Cytochem. 1987;35:627. doi: 10.1177/35.6.3033062. [DOI] [PubMed] [Google Scholar]
  • 4.Bielefeldt-Ohmann H, Babiuk LA. Bovine alveolar macrophages: functional heterogeneity among subpopulations defined by differential centrifugation on a discontinuous density gradient. J Leukoc Biol. 1986;39:167. doi: 10.1002/jlb.39.2.167. [DOI] [PubMed] [Google Scholar]
  • 5.Reference deleted
  • 6.Bierer BE, Sleckman BP, Ratnofsky SE, Burakoff SJ. The biological roles of CD2, CD4, and CD8 in T-cell activation. Annu Rev Immunol. 1989;7:579. doi: 10.1146/annurev.iy.07.040189.003051. [DOI] [PubMed] [Google Scholar]
  • 7.Brandes ME, Wakefield LM, Wahl SM. Modulation of monocyte type I transforming growth factor-ß receptors by inflammatory stimuli. J Biol Chem. 1991;266:19697. [PubMed] [Google Scholar]
  • 8.Buferne M, Luton F, Letourneur F, Hoeveler A, Couez D, Barad M, Malissen B, Schmitt-Verhulst A-M, Boyer C. Role of CD3δ in surface expression of the TCR/CD3 complex and in activation for killing analyzed with a CD3δ-negative cytotoxic T lymphocyte variant. J Immunol. 1992;148:657. [PubMed] [Google Scholar]
  • 9.Burger R, Gramatzki M. Responsiveness of the interleukin (IL)-6-dependent cell line B9 to IL11. J Immunol Methods. 1993;158:147. doi: 10.1016/0022-1759(93)90266-a. [DOI] [PubMed] [Google Scholar]
  • 10.Chantry D, Turner M, Abney E, Feldmann M. Modulation of cytokine production by transforming growth factor-ß. J Immunol. 1989;142:4295. [PubMed] [Google Scholar]
  • 11.Cherwinsky HM, Schumacher JH, Brown KD, Mosmann TR. Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies. J Exp Med. 1987;166:1229. doi: 10.1084/jem.166.5.1229. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Christmas T, Manning LS, Garlepp MJ, Musk AW, Robinson BWS. Effect of interferon alpha-2a on malignant mesothelioma. J Interferon Res. 1993;13:9. doi: 10.1089/jir.1993.13.9. [DOI] [PubMed] [Google Scholar]
  • 13.Davis MR, Manning LS, Whitaker D, Garlepp MJ, Robinson BWS. Establishment of a murine model of malignant mesothelioma. Int J Cancer. 1992;52:881. doi: 10.1002/ijc.2910520609. [DOI] [PubMed] [Google Scholar]
  • 14.Doskow JR, Wilkinson MF. CD3-γ, −δ, −ε, −ξ, T-cell receptor-α and −ß transcripts are independently regulated during thymocyte ontogeny and T-cell activation. Immunology. 1992;77:465. [PMC free article] [PubMed] [Google Scholar]
  • 15.Fan S-T, Edgington TS. Integrin regulation of leukocyte inflammatory functions. CD11b/CD18 enhancement of the tumour necrosis factor-α responses of monocytes. J Immunol. 1993;150:2972. [PubMed] [Google Scholar]
  • 16.Fargeas C, Wu CY, Nakajima T, Cox D, Nutman T, Delespesse G. Differential effect of transforming growth factor β on the synthesis of Th1- and Th2-like lymphokines by human T lymphocytes. Eur J Immunol. 1992;22:2173. doi: 10.1002/eji.1830220833. [DOI] [PubMed] [Google Scholar]
  • 17.Fitzpatrick DR, Wie J, Webb D, Bonfiglioli R, Gardner ID, Mathews JD, Bielefeldt-Ohmann H. Preferential binding ofChlamydia trachomatis to subsets of human lymphocytes and induction of interlcukin-6 and interferon-gamma. Immunol Cell Biol. 1991;69:337. doi: 10.1038/icb.1991.49. [DOI] [PubMed] [Google Scholar]
  • 18.Fitzpatrick DR, Bielefeldt-Ohmann H, Himbeck RP, Jarnicki AG, Marzo AL, Robinson BWS (1994) Transforming growth factor-beta: antisense RNA-mediated inhibition affects anchorage-independent growth, tumourigenicity and T-cell infiltration in malignant mesothelioma. Growth Factors 10 (in press) [DOI] [PubMed]
  • 19.Fulton AM. Tumour-associated macrophages. In: Heppner GH, Fulton AM, editors. Macrophages and cancer. Baton Rouge: CRC Press; 1980. pp. 97–112. [Google Scholar]
  • 20.Green LM, Reade JL, Ware CF. Rapid colorimetric assay for cell viability: application to the quantitation of cytotoxic and growth inhibitory lymphokines. J Immunol Methods. 1984;70:257. doi: 10.1016/0022-1759(84)90190-x. [DOI] [PubMed] [Google Scholar]
  • 21.Haskill JS, Yamamura Y, Radov L, Parthenais E. Are peripheral and in situ tumour immunity related? Ann NY Acad Sci. 1976;276:373. doi: 10.1111/j.1749-6632.1976.tb41662.x. [DOI] [PubMed] [Google Scholar]
  • 22.Henderson DW, Shilkin KB, Whitaker D, Attwood HD, Constance TJ, Steele RH, Leppard PJ. The pathology of malignant mesothelioma, including immunohistology and ultrastructure. In: Henderson DW, Shilkin KB, Langlois SLP, Whitaker D, editors. Malignant mesothelioma. New York: Hemisphere; 1992. p. 69. [Google Scholar]
  • 23.Hurliman J, Sarage P. Mononuclear cells infiltrating human mammary carcinomas: immunohistochemical analysis with monoclonal antibodies. Int J Cancer. 1985;35:753. doi: 10.1002/ijc.2910350610. [DOI] [PubMed] [Google Scholar]
  • 24.Jarnicki AG, Fitzpatrick DR, Marzo A, Robinson B, Bielefeldt-Ohmann H. Surface antigen and cytokine profile of tumour-infiltrating lymphocytes (TIL) in malignant mesothelioma. J Leukoc Biol. 1993;54(Suppl):90. [Google Scholar]
  • 25.Kay J, Porcelli S, Tite J, Jones B, Janeway CA. Both a monoclonal antibody and antisera specific for determinants unique to individual cloned helper T cell lines can substitute for antigen and antigen-presenting cells in the activation of T cells. J Exp Med. 1983;158:836. doi: 10.1084/jem.158.3.836. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Kelso A. Frequency analysis of lymphokine-secreting CD4+ and CD8+ T cells activated in a graft-versus-host reaction. J Immunol. 1990;145:2167. [PubMed] [Google Scholar]
  • 27.King LB, Ashwell JD. Signaling for death of lymphoid cells. Curr Opin Immunol. 1993;5:368. doi: 10.1016/0952-7915(93)90055-w. [DOI] [PubMed] [Google Scholar]
  • 28.Langerak AW, Vietsch H, Bouts MJ, Hagemeijer A, Versnel MA. A spontaneously in vitro transformed mesothelial cell line has a similar pattern of PDGF chain and PDGF receptor expression to malignant mesothelioma cell lines. Eur Respir Rev. 1993;3:170. [Google Scholar]
  • 29.Leo O, Foo M, Sachs DH, Samuelsen LE, Bluestone JA. Identification of a monoclonal antibody specific for murine T3. Proc Natl Acad Sci USA. 1987;84:1374. doi: 10.1073/pnas.84.5.1374. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Martin MS, Caignard A, Hammann A, Pelletier H, Martin F. An immunohistological study of cells infiltrating progressive and regressive tumours induced by two variant subpopulations of a rat colon cancer cell line. Int J Cancer. 1987;40:87. doi: 10.1002/ijc.2910400116. [DOI] [PubMed] [Google Scholar]
  • 31.Manning LS, Davis MR, Bielefeldt-Ohmann H, Marzo AL, Garlepp MJ, Whitaker D, Robinson BWS. Evaluation of immunogenicity of murine mesothelioma cells by immunization. Eur Resp Rev. 1993;3:234. [Google Scholar]
  • 32.Manning LS, Rose AH, Bowman RV, Christmas TI, Garlepp MJ, Robinson BWS. Immune function related to asbestos exposure and mesothelioma, and immunotherapy of mesothelioma. In: Henderson DW, Shilkin KB, Langlois SLP, Whitaker D, editors. Malignant mesothelioma. New York: Hemisphere; 1992. p. 278. [Google Scholar]
  • 33.Meade R, Askenase PW, Geba GP, Neddermann K, Jacoby RO, Pasternak RD. Transforming growth factor-β1 inhibits murine immediate and delayed type hypersensitivity. J Immunol. 1992;149:521. [PubMed] [Google Scholar]
  • 34.Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC. Alterations in signal transduction molecules in T lymphocytes from tumour-bearing mice. Science. 1992;258:1795. doi: 10.1126/science.1465616. [DOI] [PubMed] [Google Scholar]
  • 35.Mosman TR, Schumacher J, Fiorentino DF, Leverah J, Moore KW, Bond MW. Isolation of mAb specific for IL4, IL5, IL6, and a new Th2-specific cytokine synthesis inhibitory factor (CSIF; IL10) using a solid phase radioimmunosorbent assay: blocking and non-blocking anti-CSIF mAb. J Immunol. 1990;145:2938. [PubMed] [Google Scholar]
  • 36.Musk AW, Bowman RV, Christmas TI, Robinson BWS. Management of malignant mesothelioma. In: Henderson DW, Shilkin KB, Langlois SLP, Whitaker D, editors. Malignant mesothelioma. New York: Hemisphere; 1992. p. 292. [Google Scholar]
  • 37.Pabst R, Binns RM. Heterogeneity of lymphocyte homing physiology. Several mechanisms operate in the control of migration to lymphoid and non-lymphoid organs in vivo. Immunol Rev. 1989;108:83. doi: 10.1111/j.1600-065x.1989.tb00014.x. [DOI] [PubMed] [Google Scholar]
  • 38.Pinsky MR, Vincent J-L, Deviere J, Alegre M, Kahn RJ, Dupont E. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest. 1993;103:565. doi: 10.1378/chest.103.2.565. [DOI] [PubMed] [Google Scholar]
  • 39.Rao M, Lee WT, Conrad DH. Characterization of a monoclonal antibody directed against the murine B lymphocyte receptor for IgE. J Immunol. 1987;138:1845. [PubMed] [Google Scholar]
  • 40.Strassman G, Jacob CO, Evans R, Beall D, Fong M. Mechanisms of experimental cancer cachexia. Interaction between mononuclear phagocytes and colon-26 carcinoma and its relevance to IL-6-mediated cancer cachexia. J Immunol. 1992;148:3674. [PubMed] [Google Scholar]
  • 41.Strassmann G, Masui Y, Chizzonite R, Fong M. Mechanisms of experimental cancer cachexia. Local involvement of IL-1 in colon-26 tumour. J Immunol. 1993;150:2341. [PubMed] [Google Scholar]
  • 42.Tada T, Ohzeki S, Utsumi K, Takiuchi H, Muramatsu M, Li X-F, Shimizu J, Fujiwara H, Hamaoka T. Transforming growth factor-ß-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumour-bearing state. J Immunol. 1991;146:1077. [PubMed] [Google Scholar]
  • 43.Teng MN, Park BH, Koeppen HKW, Tracey KJ, Fendley BM, Schreiber H. Long-term inhibition of tumour growth by tumour necrosis factor in the absence of cachexia or T-cell immunity. Proc Natl Acad Sci USA. 1991;88:3535. doi: 10.1073/pnas.88.9.3535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Vink A, Coulie P, Warnier G, Renauld J-C, Stevens M, Donckers D, van Snick J. Mouse plasmacytoma growth in vivo: enhancement by interleukin 6 (IL-6) and inhibition by antibodies directed against IL-6 or its receptor. J Exp Med. 1992;172:997. doi: 10.1084/jem.172.3.997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Vose BM, Moore M. Human tumour-infiltrating lymphocytes. Semin Hematol. 1985;22:27. [PubMed] [Google Scholar]
  • 46.Wahl SM, Hunt DA, Wakefield LM, McCartney-Francis N, Wahl LM, Roberts AB, Sporn MB. Transforming growth factor type β induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci USA. 1987;84:5788. doi: 10.1073/pnas.84.16.5788. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Wang R, Murphy KM, Loh DY, Weaver C, Russell JH. Differential activation of antigen-stimulated suicide and cytokine production pathways in CD4+ T cells is regulated by the antigen-presenting cell. J Immunol. 1993;150:3832. [PubMed] [Google Scholar]
  • 48.Wilbanks GA, Streilein JW. Fluids from immune previleged sites endow macrophages with the capacity to induce antigenspecific immune deviation via a mechanism involving transforming growth factor-ß. Eur J Immunol. 1992;22:1031. doi: 10.1002/eji.1830220423. [DOI] [PubMed] [Google Scholar]
  • 49.Yagita H, Nakamura T, Karasuyama H, Okumura K. Monoclonal antibodies specific for murine CD2 reveal its presence on B as well as T cells. Proc Natl Acad Sci USA. 1989;86:645. doi: 10.1073/pnas.86.2.645. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Yorochko AD, Burger CJ, Elgert KD. Tumour modulation of autoreactivity: decreased macrophage and autoreactive T cell interactions. Cell Immunol. 1990;127:105. doi: 10.1016/0008-8749(90)90118-b. [DOI] [PubMed] [Google Scholar]
  • 51.Zanders ED, Lamb JR, Feldmann M, Green N, Beverley PCL. Tolerance of T-cell clones is associated with membrane antigen changes. Nature. 1983;303:625. doi: 10.1038/303625a0. [DOI] [PubMed] [Google Scholar]
  • 52.Zugmaier G, Paik S, Wilding G, Knabbe C, Bano M, Lupu R, Deschauer B, Simpson S, Dickson RB, Lippman M. Transforming growth factor β1 induces cachexia and systemic fibrosis without an antitumour effect in nude mice. Cancer Res. 1991;51:3590. [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES